company background image
RCE logo

Recce Pharmaceuticals ASX:RCE Stock Report

Last Price

AU$0.54

Market Cap

AU$125.1m

7D

3.8%

1Y

17.4%

Updated

13 Oct, 2024

Data

Company Financials +

Recce Pharmaceuticals Ltd

ASX:RCE Stock Report

Market Cap: AU$125.1m

RCE Stock Overview

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

RCE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Recce Pharmaceuticals Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Recce Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.54
52 Week HighAU$0.69
52 Week LowAU$0.41
Beta1.05
11 Month Change5.88%
3 Month Change18.68%
1 Year Change17.39%
33 Year Change-43.16%
5 Year Change107.69%
Change since IPO80.00%

Recent News & Updates

Recent updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Nov 01
We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Feb 13
Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Jul 28
We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Dec 07
Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Mar 08
Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Feb 01
Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

Dec 09
Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

Shareholder Returns

RCEAU PharmaceuticalsAU Market
7D3.8%-4.2%0.8%
1Y17.4%80.4%16.5%

Return vs Industry: RCE underperformed the Australian Pharmaceuticals industry which returned 80.4% over the past year.

Return vs Market: RCE matched the Australian Market which returned 16.5% over the past year.

Price Volatility

Is RCE's price volatile compared to industry and market?
RCE volatility
RCE Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement8.9%
10% most volatile stocks in AU Market17.2%
10% least volatile stocks in AU Market3.6%

Stable Share Price: RCE has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: RCE's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aJames Grahamwww.recce.com.au

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use.

Recce Pharmaceuticals Ltd Fundamentals Summary

How do Recce Pharmaceuticals's earnings and revenue compare to its market cap?
RCE fundamental statistics
Market capAU$125.07m
Earnings (TTM)-AU$17.66m
Revenue (TTM)AU$5.03m

24.9x

P/S Ratio

-7.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RCE income statement (TTM)
RevenueAU$5.03m
Cost of RevenueAU$7.22m
Gross Profit-AU$2.19m
Other ExpensesAU$15.47m
Earnings-AU$17.66m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.076
Gross Margin-43.52%
Net Profit Margin-351.24%
Debt/Equity Ratio-101.7%

How did RCE perform over the long term?

See historical performance and comparison